Idera pharmaceuticals, inc. (IDRA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Alliance revenue

-

-

-

1,448

-

99

145

163

255

173

164

187

378

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Alliance revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

323

301

294

190

20

5

34

2

30

38

3

4

7

29

7

11

3

28

9

8

4

33

8

5,089

4,386

Operating expenses:
Research and development

9,510

-18,383

8,359

10,024

8,102

8,545

8,860

10,880

13,556

10,365

10,912

17,891

11,485

11,007

9,393

10,128

9,296

8,565

7,454

8,960

8,720

8,245

6,678

5,637

6,933

3,640

2,510

1,997

2,328

3,078

3,278

3,504

3,813

5,700

3,574

4,142

4,553

7,786

6,961

General and administrative

3,642

-5,918

3,023

2,895

3,143

3,955

3,984

4,000

3,481

3,700

3,919

3,888

4,081

3,531

3,907

3,778

3,916

3,708

4,030

3,821

3,837

3,686

2,873

2,730

2,043

2,436

2,179

1,599

1,527

1,265

1,477

1,848

1,689

1,539

1,948

2,166

2,286

2,193

2,784

Merger-related costs, net

-

-

-

-

-

0

-3,836

1,583

3,498

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restructuring costs

-

-50

5

45

131

-

3,017

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

13,152

-24,351

11,387

12,964

11,376

12,595

12,025

16,463

20,535

15,193

14,831

21,779

15,566

14,538

13,300

13,906

13,212

12,273

11,484

12,781

12,557

11,931

9,551

8,367

8,976

6,076

4,689

3,596

3,855

4,343

4,755

5,352

5,502

7,239

5,522

6,308

6,839

9,979

9,745

Loss from operations

-13,152

22,903

-11,387

-11,516

-11,376

-12,496

-11,880

-16,300

-20,280

-15,020

-14,667

-21,592

-15,188

743

-12,977

-13,605

-12,918

-12,083

-11,464

-12,776

-12,523

-11,929

-9,521

-8,329

-8,973

-6,072

-4,682

-3,567

-3,848

-4,332

-4,752

-5,324

-5,493

-7,231

-5,518

-6,275

-6,831

-4,890

-5,359

Other income (expense):
Interest income

125

-588

249

339

404

330

277

271

211

118

159

144

153

95

90

110

120

118

123

75

41

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

0

0

4

7

10

11

13

16

17

19

21

23

-

27

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant revaluation income

1,101

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Future tranche right revaluation income

20,711

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

569

109

1,318

-1,321

-

0

-

-

-

-

Investment income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14

16

15

-

2

2

2

1

2

2

4

2

2

5

21

31

29

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-27

-27

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency exchange gain (loss)

32

-6

5

1

-2

16

-2

2

-19

-14

-11

-10

-6

1

3

31

-2

-1

3

9

28

17

52

5

-3

-23

-58

-26

39

-36

-28

117

-76

95

27

-12

-35

148

34

Net income (loss)

8,817

22,309

-11,133

-11,176

-10,974

-12,150

-11,605

-16,031

-20,095

-14,926

-14,530

-21,471

-15,057

822

-12,903

-13,485

-12,823

-11,990

-11,365

-12,719

-12,481

-12,437

-9,455

-8,308

-8,961

-6,090

-4,738

-3,591

-3,807

-3,798

-4,669

-3,887

-6,886

-5,160

-5,489

-6,282

-6,845

-4,711

-5,296

Net income (loss) per share applicable to common stockholders (Note 12)
Basic

0.27

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.25

-

-0.20

-0.23

-0.25

-0.18

-0.23

Diluted

0.22

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.25

-

-0.20

-0.23

-0.25

-0.18

-0.23

Weighted-average number of common shares used in computing net income (loss) per share applicable to common stockholders
Basic

30,300

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

27,637

-

27,632

27,619

27,604

25,980

23,473

Diluted

33,010

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

27,637

-

27,632

27,619

27,604

25,980

23,473

Deemed dividend related to December 2019 Private Placement (see Note 7)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

97

119

118

185

279

278

2,030

279

2,730

160

160

160

-

0

0

-

-

-

Net loss attributable to common stockholders

-

-

-11,133

-11,176

-10,974

-12,150

-11,605

-16,031

-20,095

-14,926

-14,530

-21,471

-15,057

822

-12,903

-13,485

-12,823

-

-11,365

-

-

-11,496

-9,574

-8,426

-9,146

-6,369

-5,016

-5,621

-4,086

-6,528

-4,829

-4,047

-7,046

-9,708

-5,489

-6,282

-6,845

-

-

Net loss per share applicable to common stockholders - basic and diluted (Note 17)

-

-

-0.39

-0.39

-0.40

-0.42

-0.43

-0.59

-0.81

-1.32

-0.78

-1.15

-0.10

-2.09

-0.10

-0.11

-0.11

-0.09

-0.10

-0.11

-0.12

-0.14

-0.11

-0.10

-0.12

-0.07

-0.11

-0.15

-0.15

-

-0.17

-0.15

-

-

-

-

-

-

-

Weighted-average number of common shares used in computing net loss per share applicable to common stockholders - basic and diluted

-

-

28,847

28,461

27,676

27,217

27,175

27,133

24,879

-107,780

18,704

18,676

149,100

-300,196

121,389

121,323

121,284

119,051

118,248

118,002

105,067

87,802

84,527

82,961

76,018

64,212

45,720

38,048

27,644

-

27,640

27,638

-

-

-

-

-

-

-

Comprehensive income (loss):
Net income (loss)

8,817

22,309

-11,133

-11,176

-10,974

-12,150

-11,605

-16,031

-20,095

-14,926

-14,530

-21,471

-15,057

822

-12,903

-13,485

-12,823

-11,990

-11,365

-12,719

-12,481

-

-9,455

-8,308

-8,961

-6,090

-4,738

-3,591

-3,807

-3,798

-4,669

-3,887

-6,886

-5,160

-5,489

-6,282

-6,845

-4,711

-5,296

Unrealized gain on available-for-sale securities

-

1

-1

0

2

-

-

-

-

2

-1

0

16

-42

13

12

134

-

50

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other comprehensive income

-

1

-1

0

2

-

-

-

-

2

-1

0

16

-

-

-

-

-

-

-

18

-

-

-

11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain (loss) on available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-78

18

-

-5

-1

11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in unrealized loss and decrease in unrealized gain on available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-4

-9

-

-

Other comprehensive income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-4

-9

-

-

Comprehensive income (loss):

8,817

22,310

-11,134

-11,176

-10,972

-12,150

-11,605

-16,031

-20,095

-14,924

-14,531

-21,471

-15,041

780

-12,890

-13,473

-12,689

-12,097

-11,315

-12,797

-12,463

-11,933

-9,460

-8,309

-8,950

-6,097

-4,738

-3,591

-3,807

-3,798

-4,669

-3,887

-6,886

-5,160

-5,489

-6,286

-6,854

-

-